<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950882</url>
  </required_header>
  <id_info>
    <org_study_id>PXL770-003</org_study_id>
    <nct_id>NCT03950882</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics of PXL770 after 4 weeks of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed in subjects with Nonalcoholic Fatty Liver Disease. The primary
      endpoint will be the assessment of PXL770 exposure in plasma.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 27, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of PXL770 after 4 weeks of treatment</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <description>AUC : Area under the plasma concentration curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety and tolerability</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Nonalcoholic Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PXL770 Dose 1 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PXL770 Dose 2 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXL770</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects have given written informed consent

          -  Body mass index (BMI): ≥ 25 kg/m²

          -  Hepatic steatosis (CAP ≥ 300)

          -  Insulin-resistant but not diabetic subjects

          -  Fasting plasma glucose &lt;126 mg/dL

          -  Glomerular filtration rate (eGFR) ≥ 60 mL/[min*1.73 m²]

          -  Alanine amino transferase (ALT) &gt; 20 IU/L in females and &gt; 30 IU/L in males

          -  Effective contraception

        Exclusion Criteria:

          -  Evidence of another form of liver disease

          -  Evidence of liver cirrhosis

          -  Evidence of hepatic impairment

          -  Positive serologic evidence of current infectious liver disease

          -  History of excessive alcohol intake

          -  Acute cardiovascular disease with 24 weeks prior to screening

          -  Uncontrolled high blood pressure

          -  Any disease which in the Investigator's opinion which in the Investigator's opinion
             would exclude the patient from the study

          -  Use of non-permitted concomitant medication

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>POXEL SA</last_name>
  </overall_contact>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

